A detailed history of Vanguard Group Inc transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,117,916 shares of HBIO stock, worth $4.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,117,916
Previous 2,152,147 1.59%
Holding current value
$4.98 Million
Previous $9.13 Million 33.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.77 - $4.63 $94,819 - $158,489
-34,231 Reduced 1.59%
2,117,916 $6.04 Million
Q1 2024

May 10, 2024

BUY
$4.02 - $5.39 $199,295 - $267,214
49,576 Added 2.36%
2,152,147 $9.13 Million
Q4 2023

Feb 14, 2024

BUY
$4.0 - $5.49 $152,676 - $209,547
38,169 Added 1.85%
2,102,571 $11.2 Million
Q3 2023

Nov 14, 2023

BUY
$4.0 - $5.82 $409,540 - $595,880
102,385 Added 5.22%
2,064,402 $8.88 Million
Q2 2023

Aug 14, 2023

BUY
$4.19 - $6.16 $913,507 - $1.34 Million
218,021 Added 12.5%
1,962,017 $10.8 Million
Q1 2023

May 15, 2023

BUY
$2.45 - $4.22 $1.19 Million - $2.05 Million
486,198 Added 38.65%
1,743,996 $7.32 Million
Q4 2022

Feb 10, 2023

SELL
$2.12 - $2.86 $594,628 - $802,187
-280,485 Reduced 18.23%
1,257,798 $3.48 Million
Q2 2022

Aug 12, 2022

SELL
$3.28 - $6.42 $1.27 Million - $2.48 Million
-386,234 Reduced 20.07%
1,538,283 $5.54 Million
Q1 2022

May 13, 2022

BUY
$5.16 - $7.14 $1.13 Million - $1.56 Million
218,832 Added 12.83%
1,924,517 $12 Million
Q4 2021

Feb 14, 2022

SELL
$6.37 - $8.18 $611,647 - $785,443
-96,020 Reduced 5.33%
1,705,685 $12 Million
Q3 2021

Nov 12, 2021

SELL
$6.98 - $8.47 $866,657 - $1.05 Million
-124,163 Reduced 6.45%
1,801,705 $12.6 Million
Q2 2021

Aug 13, 2021

BUY
$5.44 - $8.4 $10.5 Million - $16.2 Million
1,925,868 New
1,925,868 $16 Million

Others Institutions Holding HBIO

About HARVARD BIOSCIENCE INC


  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $97.8M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.